P1677: DEFINING KEY QUALITY OF LIFE METRICS IN ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS ENROLLED IN LARGE-SCALE UK NCRI AML TRIALS
Main Authors: | Pramila Krishnamurthy, Myrsini Gianatsi, Sophie Wintrich, Abin Thomas, Lynn Quek, Austin Kulasekararaj, Priyanka Mehta, Sreetharan Munisamy, Nigel Russell, Mike Dennis, Elspeth Payne, Ian Thomas |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000973580.07128.32 |
Similar Items
-
S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
by: Steven Knapper, et al.
Published: (2023-08-01) -
P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
by: Nicola Potter, et al.
Published: (2023-08-01) -
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
by: Burnett, A, et al.
Published: (2018) -
The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial
by: Burnett, AK, et al.
Published: (2018) -
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
by: Freeman, SD, et al.
Published: (2023)